{
  "docId": "019de075-8d44-7401-b489-ee436db9a207",
  "docSlug": "66ec60e76d61a423395d466c32dc56fb",
  "documentTitle": "Exscientia | Investor Presentation Deck | 75 slides",
  "authorId": "exscientia",
  "authorName": "Exscientia",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 60,
  "pageCount": 75,
  "prevPage": 59,
  "nextPage": 61,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 66,
  "notes": "The chart shows a statistically significant difference (****) between the vehicle control and the treatment groups.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-8d44-7401-b489-ee436db9a207/60",
  "deckHref": "/decks/019de075-8d44-7401-b489-ee436db9a207",
  "deckJsonHref": "/decks/019de075-8d44-7401-b489-ee436db9a207.json",
  "deckAnchorHref": "/decks/019de075-8d44-7401-b489-ee436db9a207#slide-60",
  "components": [
    {
      "bbox": {
        "h": 0.7,
        "w": 0.53,
        "x": 0.04,
        "y": 0.225
      },
      "kind": "chart",
      "text": "Tumour Volume (mean +/- SD) Data from Model-informed Intermittent Regimen Study",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fa09d7a7-5dae-4477-ad2a-fcdebbe9f408",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.35,
        "x": 0.59,
        "y": 0.28
      },
      "kind": "list",
      "text": "Dose regimens were selected based on model-based predictions of anti-tumour efficacy with minimal impact on platelets. Achieving this balance is anticipated to be more challenging with irreversible inhibitors, protein degraders and even reversible inhibitors with long human half-lives. The anti-tumour efficacy predictions were strongly correlated with outcomes",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b0a735b5-719f-404e-ae15-04c2c204c102",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.85,
        "x": 0.07,
        "y": 0.13
      },
      "kind": "title",
      "text": "Shorter half-life and reversibility enables exploration of different dosing schedules",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "efbe6ec5-54e8-4954-88ef-e019262c4f8e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.07,
        "y": 0.06
      },
      "kind": "title",
      "text": "Efficacy maintained with intermittent dosing",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7493532d-dcd4-4703-9c46-f6adab2e26b0",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}